A new study suggests that a key group of transcription factors are 'druggable,' including several that could be targeted to treat cancer, metabolic disease, or autoimmune conditions.
CURRENT ISSUE - April 2026
Why Performance, Cost, and Environmental Impact Now Compete in Procurement